Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice

References

• Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530–7
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261–9
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617–27
   PubMed Web of Science ®Google Scholar
• McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002;63:207–13
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159:1–50
   Web of Science ®Google Scholar
• Ketter TA, Wang PW, Nowakowska C, et al. Advances in the treatment of acute mania. In: Ketter TA, editor. Advances in treatment of bipolar disorder, vol. 24. Washington, DC: American Psychiatric Publishing, Inc., 2005, pp.11–55
   Google Scholar
• Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 2003;64: 532–9
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Kupfer DJ, Houck P, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J of Psychiatry 2003;160:112–7
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005;13:322–7
   Google Scholar
• Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2003;163:427–36
   PubMed Web of Science ®Google Scholar
• Wang PW, Sachs GS, Zarate CA, et al. Overweight and obesity in bipolar disorders. J Psychiatr Res 2006; March 3 [Epub ahead of print]
   Google Scholar
• Elmslie JL, Silverstone JT, Mann JI, et al. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000;61:179–84
   PubMed Web of Science ®Google Scholar
• Montanez A, Ruskin JN, Hebert PR, et al. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med 2004;164:943–8
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601
   PubMed Web of Science ®Google Scholar
• Elmslie JL, Mann JI, Silverstone JT, et al. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001;62:486–91
   PubMed Web of Science ®Google Scholar
• Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63:1148–55
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481–9
   PubMed Web of Science ®Google Scholar
• Peselow ED, Dunner DL, Fieve RR, et al. Lithium carbonate and weight gain. J Affect Disord 1980;2:303–10
   PubMed Web of Science ®Google Scholar
• Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011–7
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686–96
   PubMed Web of Science ®Google Scholar
• Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66:111–21
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania – a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15:573–85
   PubMed Web of Science ®Google Scholar
• Marcus RN, Carson W, McQuade RD, et al. Overview of safety and tolerability of aripiprazole in acute mania. Poster presented at: 157th American Psychiatric Association Annual Meeting, 1–6 May 2004, New York
   Google Scholar
• Sanger TM, Grundy SL, Gibson PJ, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001;62:273–81
   PubMed Web of Science ®Google Scholar
• Rosack J. FDA to require diabetes warning on antipsychotics. Psychiatr News 2003;38:1–5
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626–37
   PubMed Web of Science ®Google Scholar
• Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006;8:175–81
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 2006;163:1199–201
   PubMed Web of Science ®Google Scholar
• Weisler RH, Hirschfeld R, Cutler AJ, et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomized, double-blind, placebo-controlled trials. CNS Drugs 2006;20:219–31
   PubMed Web of Science ®Google Scholar
• Ketter TA, Kalali AH, Weisler RH, et al. A 6-month, multicenter, open-label evaluation of extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65:668–73
   PubMed Web of Science ®Google Scholar
• Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85:114–8
   Google Scholar
• Baptista T, Teneud L, Contreras Q, et al. Lithium and body weight gain. Pharmacopsychiatry 1995;28:35–44
   PubMed Web of Science ®Google Scholar
• Masand PS, Fazal FS, Patkar AA. Safety considerations in pharmacotherapy of bipolar disorder. CNS Spectr 2004;9: 16–26
   Google Scholar
• Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013–24
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1–93
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19–28
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004;24:S1–6
   Google Scholar